Utilization of triptans in Sweden; analyses of over the counter and prescription sales

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 12, 2014, Pages 1288-1293

  von Euler, Mia ^a,b   Keshani, Sara ^a,c   Baatz, Katarina ^d   Wettermark, Bjorn ^c,e  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d NATIONAL BOARD OF HEALTH AND WELFARE   (Sweden)

^e STOCKHOLM COUNTY COUNCIL   (Sweden)

Author keywords

Drug utilization; Migraine; Over the counter; Pharmacoepidemiology; Prescription; Triptan

Indexed keywords

NON PRESCRIPTION DRUG; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN; TRYPTAMINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DRUG MARKETING; DRUG UTILIZATION; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; SWEDEN; ECONOMICS; HISTORY; MIGRAINE DISORDERS; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DRUG UTILIZATION; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NONPRESCRIPTION DRUGS; SWEDEN; TRYPTAMINES;

EID: 84914112887     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3681     Document Type: Article

References (40)

1. Smitherman TA, Burch R, Sheikh H, et al. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache 2013; 53: 427-436.
2. Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain 2010; 11: 289-299.
3. Dahlof C, Linde M. One-year prevalence of migraine in Sweden: a population-based study in adults. Cephalalgia 2001; 21: 664-671.
4. Evers S, Afra J, Frese A, et al. European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol 2009; 16: 968-981.
5. Goadsby PJ. The pharmacology of headache. Prog Neurobiol 2000; 62: 509-525.
6. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358: 1668-1675.
7. Tfelt-Hansen PC. Unpublished clinical trials with sumatriptan. Lancet 2009; 374: 1501-1502.
8. FASS (Farmacevtiska specialiteter i Sverige). Available at: www.FASS.se [10 January 2014].
9. Hedberg N, Ramsberg J. Review of medications against migraines. Pharmaceutical benefits board, 2005. Available at: www.tlv.se [6 February 2013].
10. Wettermark B, Godman B, Andersson K, et al. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics 2008; 26: 537-550.
11. Johnston MM, Rapoport AM. Triptans for the management of migraine. Drugs 2010; 70: 1505-1518.
12. Tfelt-Hansen P, Steiner TJ. Over-the-counter triptans for migraine: what are the implications? CNS Drugs 2007; 21: 877-883.
13. Hall GC, Brown MM, Mo J, et al. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004; 62: 563-568.
14. Bigal ME, Golden W, Buse D, et al. Triptan use as a function of cardiovascular risk. A population-based study. Headache 2010; 50: 256-263.
15. Wettermark B, Hammar N, Michaelfored C, et al. The new Swedish Prescribed Drug Register-Opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726-735.
16. WHO Collaborating Center for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 2012. Oslo 2011. Available at: www.whocc.no [4 July 2012].
17. Hallas J, Stovring H. Templates for analysis of individual level prescription data. Basic Clin Pharmacol Toxicol 2006; 98: 260-265.
18. Levin LÅ, Andersson D, Anell A, et al. Styrformer för effektiv läkemedelsanvändning. Center for Medical Technology Assessment report 2010, vol. 2. Linköping, Linköping University Electronic Press, 2011.
19. Walker R, Hinchliffe A. Prescribing and sale of ophthalmic chloramphenicol following reclassification to over-the-counter availability. Int J Pharm Pract 2010; 18: 269-274.
20. Andrade SE, Gurwitz JH, Fish LS. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of H2-receptor antagonists. Med Care 1999; 37: 424-430.
21. Sullivan PW, Nair KV, Patel BV. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy. Am J Manag Care 2005; 11: 374-382.
22. Filion KB, Delaney JA, Brophy JM, et al. The impact of over-the-counter simvastatin on the number of statin prescriptions in the United Kingdom: a view from the General Practice Research Database. Pharmacoepidemiol Drug Saf 2007; 16: 1-4.
23. Antonaci F, Dumitrache C, De Cillis I, et al. A review of current European treatment guidelines for migraine. J Headache Pain 2010; 11: 13-19.
24. Gaist D, Tsiropoulos I, Sindrup SH, et al. Inappropriate use of sumatriptan: population based register and interview study. BMJ 1998; 316: 1352-1353.
25. Dekker F, Wiendels NJ, de Valk V, et al. Triptan overuse in the Dutch general population: a nationwide pharmaco-epidemiology database analysis in 6.7 million people. Cephalalgia 2011; 31: 943-952.
26. Panconesi A, Pavone E, Vacca F, Vaiani M, Banfi R. Triptans in the Italian population: a drug utilization study and a literature review. J Headache Pain 2008; 9: 71-76.
27. Messali A, Owens G, Bloudek L, Kori S, Cole A, Chia J. Health care resource utilization following initiation of a triptan: a retrospective claims analysis. J Manag Care Pharm 2014; 20: 368-375.
28. Panconesi A, Pavone E, Franchini M, Mennuti N, Bartolozzi M, Guidi L, Banfi R. Triptans: low utilization and high turnover in the general population. Cephalalgia 2010; 30: 576-581.
29. Pavone E, Banfi R, Vaiani M, et al. Patterns of triptans use: a study based on the records of a community pharmaceutical department. Cephalalgia 2007; 27: 1000-1004.
30. Loikas D, Wettermark B, von Euler M, et al. Marked differences in drug utilization between men and women? A cross sectional analysis of all dispensed drugs in Sweden. BMJ Open 2013; 3. pii: e002378.
31. Jonsson PM, Schmidt I, Sparring V, et al. Gender equity in health care in Sweden-minor improvements since the 1990s. Health Policy 2006; 77: 24-36.
32. Anell A, Persson U. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making? Eur J Health Econ 2005; 6: 274-279.
33. Vitols S, Vetr A, Tomson T. It's possible to influence prescriptions patterns by producer-independent information. Lakartidningen 2004; 101: 2573-2575.
34. Dental and Pharmaceuticals Benefits Agency. Decision on restricted reimbursement for triptans from October 15, 2010. Available at: www.tlv.se [20130206].
35. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22: 633-658.
36. Bigal M, Rapoport A, Aurora S, et al. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache 2007; 47: 475-479.
37. Katić BJ, Rajagopalan S, Ho TW, et al. Triptan persistency among newly initiated users in a pharmacy claims database. Cephalalgia 2011; 31: 488-500.
38. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLD) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163-2196.
39. Olesen J, Bousser M-G, Diener H-C, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 6742-6774.
40. Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 2012; 19: 703-711.